HIV treatment and care among Italian inmates: a one-month point survey

BMC Infectious Diseases

Table 2 Antiretroviral regimens received by the 275 HIV-infected inmates on ART

ANTIRETROVIRAL DRUGS	n (%)
Protease inhibitors (PI)
Atazanavir	88 (32.0 %)
Lopinavir	51 (18.5 %)
Darunavir	23 (8.4 %)
Fosamprenavir	9 (3.3 %)
Saquinavir	1 (0.4)
Total	172 (62.6 %)
Non nucleoside reverse trascriptase inhibitors (NNRTI)
Efavirenz	50 (18.2 %)
Nevirapine	9 (3.3 %)
Rilpivirine	8 (2.9 %)
Etravirine	5 (1.8 %)
Total	72 (26.2 %)
3 Nucleoside reverse transriptase inhibitors (NRTI)
Abacavir-Lamivudine-Zidovudine	6 (2.2 %)
Integrase inhibitors (INI)
Raltegravir	24 (8.7 %)
CCR5 inhibitors
Maraviroc	1 (0.4 %)
NRTI backbone
Tenofovir disoproxilfumarate-emtricitabine	194 (70.5 %)
Abacavir-lamivudine	41 (14.9 %)
Zidovudine-lamivudine	12 (4.4 %)
Other	28 (10.2 %)

ISSN: 1471-2334